Longeveron Inc. (NASDAQ: LGVN) announced that data regarding its Lomecel-B™ therapy for Alzheimer's disease will be presented as a late-breaking poster at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain, from October 29 to November 1, 2024. The poster, titled "Lomecel-B inhibition of MMP14 activity predicts Lomecel-B bioactivity in the treatment of mild Alzheimer’s disease," highlights potential mechanistic and clinical insights into the development of cell-based therapies for Alzheimer's.
Lomecel-B and Alzheimer's Disease
Alzheimer's disease, a progressive neurodegenerative disorder, affects millions worldwide. Current treatments offer limited symptomatic relief, underscoring the urgent need for innovative therapeutic approaches. Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy, is derived from bone marrow of healthy, young adult donors. MSCs are known for their role in tissue repair and secretion of bioactive factors that are immunomodulatory and regenerative.
Longeveron believes Lomecel-B has multiple potential mechanisms of action that may lead to anti-inflammatory, pro-vascular regenerative responses, and therefore may have broad application for a range of rare and aging related diseases.
Presentation Details
The late-breaking poster presentation is scheduled for Tuesday, October 29, 2024, from 3:00 p.m. CEST to Wednesday, October 30, 5:00 p.m. CEST. The presentation falls under the theme of "New Therapies and Clinical Trials."
The abstract of the poster will be included in the special CTAD edition of the Journal of Prevention of Alzheimer’s Disease (JPAD), the official journal of the CTAD conference.
About Longeveron
Longeveron is a clinical-stage biotechnology company focused on developing regenerative medicines for unmet medical needs. Their lead investigational product, Lomecel-B, is currently being explored for hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Aging-related Frailty. Lomecel-B has received several U.S. FDA designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations for HLHS, and Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for AD.
Wa’el Hashad, CEO of Longeveron, stated, “We are excited to have been selected to present important Lomecel-B™ data at a leading forum for Alzheimer’s research and clinical investigation. We believe the findings offer potential mechanistic and clinical insights in the development of cellular-based therapy for Alzheimer’s disease.”
